Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QTX3544 in KRAS G12V-mutant advanced solid tumors
NCT06715124Phase 1Active, not recruiting
- Sponsor
- Quanta Therapeutics
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label trial of QTX3544 in solid tumor (4 arms), sponsored by Quanta Therapeutics. Primary endpoints: Treatment-emergent Adverse Events at 2 years and Dose Limiting Toxicities at 21 days. Started Jan 2025; status: active, not recruiting.
02
Drugs
QTX3544
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06715124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715124.